Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Nabriva Therapeutics stock

Learn how to easily invest in Nabriva Therapeutics stock.

Nabriva Therapeutics plc is a biotechnology business based in the US. Nabriva Therapeutics shares (NBRV) are listed on the NASDAQ and all prices are listed in US Dollars. Nabriva Therapeutics employs 72 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Nabriva Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NBRV – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Nabriva Therapeutics stock price (NASDAQ: NBRV)

Use our graph to track the performance of NBRV stocks over time.

Nabriva Therapeutics shares at a glance

Information last updated 2022-01-17.
Latest market close$0.45
52-week range$0.52 - $3.49
50-day moving average $0.78
200-day moving average $1.15
Wall St. target price$2.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.62

Buy Nabriva Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Nabriva Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nabriva Therapeutics price performance over time

Historical closes compared with the close of $0.4504 from 2022-01-24

1 week (2022-01-18) -11.51%
1 month (2021-12-23) -26.16%
3 months (2021-10-25) -59.79%
6 months (2021-07-23) -60.14%
1 year (2021-01-25) -85.47%
2 years (2020-01-24) -66.64%
3 years (2019-01-25) 1.92
5 years (2017-01-25) 8.21

Nabriva Therapeutics financials

Revenue TTM $22.1 million
Gross profit TTM $-10,841,000
Return on assets TTM -46.19%
Return on equity TTM -108.96%
Profit margin -245.41%
Book value $1.17
Market capitalisation $30.3 million

TTM: trailing 12 months

Nabriva Therapeutics share dividends

We're not expecting Nabriva Therapeutics to pay a dividend over the next 12 months.

Have Nabriva Therapeutics's shares ever split?

Nabriva Therapeutics's shares were split on a 1:10 basis on 2 December 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nabriva Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Nabriva Therapeutics shares which in turn could have impacted Nabriva Therapeutics's share price.

Nabriva Therapeutics share price volatility

Over the last 12 months, Nabriva Therapeutics's shares have ranged in value from as little as $0.519 up to $3.49. A popular way to gauge a stock's volatility is its "beta".

NBRV.US volatility(beta: 1.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nabriva Therapeutics's is 1.6163. This would suggest that Nabriva Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Nabriva Therapeutics overview

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI). It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. .

Frequently asked questions

What percentage of Nabriva Therapeutics is owned by insiders or institutions?
Currently 0.45% of Nabriva Therapeutics shares are held by insiders and 14.719% by institutions.
How many people work for Nabriva Therapeutics?
Latest data suggests 72 work at Nabriva Therapeutics.
When does the fiscal year end for Nabriva Therapeutics?
Nabriva Therapeutics's fiscal year ends in December.
Where is Nabriva Therapeutics based?
Nabriva Therapeutics's address is: 25-28 North Wall Quay, Dublin, Ireland, 1
What is Nabriva Therapeutics's ISIN number?
Nabriva Therapeutics's international securities identification number is: IE00BL53QQ85
What is Nabriva Therapeutics's CUSIP number?
Nabriva Therapeutics's Committee on Uniform Securities Identification Procedures number is: 62957M104

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site